HARMONY Partner, WP2/WP7 Co-leader Aliki Taylor from Takeda will present the HARMONY Alliance at the R&D Data Intelligence Leaders Forum in Basel, organized on 23 and 24 January 2018. The “R&D Data Intelligence Leaders Forum” is focussed on senior decision-makers, researchers and technologists, looking to make the shift towards an integrated R&D and data strategy and for those looking to improve their implementation of data-driven approaches to enhance R&D decision-making and intelligence.
Aliki Taylor will present on Day 2 of the Leaders Forum on 24 January 2018 at 08:40 hrs, during stream 2 about Clinical & Patient Level-Data Excellence.
Already interested to hear her view? Listen to the video interview:
Find out more about this meeting organized by Next Level Pharma.
Direct link to the Leaders Forum agenda,
You can find the HARMONY presentation listed on page 7.
Would you like to connect with HARMONY in Basel?
Let us know by sending an email to communications@harmony-alliance.eu.
About the R&D Data Intelligence Leaders Forum
Achieving excellence with R&D data will enable the life sciences industry to increase the speed and quality of innovation and is thus a major source of competitive advantage. Whether researchers and informaticians deal with “big data,” “deep data” or just put their data to smarter use, it is clear that the future of R&D is dependent on both smart technologies and clever researchers. The rapid progress of innovation in software and powerful hardware now allows human researchers to interpret masses of amounts of raw data in unique ways and is redefining the R&D business model. The benefits range from discovery and “omics” research, through to clinical trials and to real patients in the real-world. However, it is major technical, financial and operational challenge to turn “messy” data into structured data, that can be used for advanced analytics that can spot opportunities and achieve true insights. Some of the most promising areas of technological innovation making rapid progress include, for example, artificial intelligence, machine learning, cloud computing and the blockchain (distributed ledgers). There is also huge potential for efficient collaborations between the life science industry, technology companies, academic researchers, health systems, physicians and health insurers.
A deeper convergence between key stakeholders and advanced technologies will facilitate the discovery and development of powerful therapies, devices and advanced diagnostics to benefit patients. The “R&D Data Intelligence Leaders Forum” is targeted at senior decision-makers, researchers and technologists, looking to make the shift towards an integrated R&D and data strategy and for those looking to improve their implementation of datadriven approaches to enhance R&D decision-making and intelligence.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
